In addition, ponatinib and pazopanib have been found to specifically block necroptosis, but not apoptosis by targeting RIPK1/3 in human cells [43], and they were also recently proposed as possible candidates in clinical therapy of various cancer types as listed in Table 3. This evidence concerns the gene RIPK1 and cancer.